Since EPH signalling seems to sustain the oncogenic and radioresistant phenotype of ERMS by regulating several molecular mechanisms [50] as schematized in Fig. 9, the combined use of GLPG1790 and RT may represent an attractive strategy to make clinical treatment of ERMS tumours more effective. This evidence concerns the gene EPHA1 and embryonal rhabdomyosarcoma.